Related references
Note: Only part of the references are listed.Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
Eliano Pio Navarese et al.
ANNALS OF INTERNAL MEDICINE (2015)
A comparison of European and US guidelines for familial hypercholesterolaemia
Zeljko Reiner
CURRENT OPINION IN LIPIDOLOGY (2015)
Adverse Effects of Statins - Myths and Reality
Iveta Simic et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Similarities and differences between European and United States guidelines for the management of dyslipidaemias
Zeljko Reiner
KARDIOLOGIA POLSKA (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
Michael J. Koren et al.
POSTGRADUATE MEDICINE (2015)
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Resistance and intolerance to statins
Z. Reiner
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey
Zeljko Reiner et al.
ATHEROSCLEROSIS (2013)
Prevalence and types of persistent dyslipidemia in patients treated with statins
Zeljko Reiner et al.
CROATIAN MEDICAL JOURNAL (2013)
Statins in the primary prevention of cardiovascular disease
Zeljko Reiner
NATURE REVIEWS CARDIOLOGY (2013)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
